Tevogen Bio Holdings Inc. (TVGN)
| Market Cap | 353.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.68M |
| Shares Out | 164.61M |
| EPS (ttm) | -3.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,077 |
| Open | 2.180 |
| Previous Close | 2.285 |
| Day's Range | 2.130 - 2.230 |
| 52-Week Range | 2.130 - 21.090 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 20, 2024 |
About TVGN
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey. [Read more]
Financial Performance
Financial StatementsNews
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Tevogen's Chief Scientific Officer explains the company's oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio') (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investo...
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Tevogen Bio Announces Series A-1 Preferred Stock Investment
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) imm...
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services...
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company's Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken str...
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) Tevogen's ExacTcell platform was developed to harness the killing ability of naturally occurring cytotoxic T lym...
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times ...
Tevogen Bio Announces $8 Million Equity Investment
WARREN, N.J.--(BUSINESS WIRE)--On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, geneti...
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T c...
Semper Paratus Acquisition Corporation's Shareholders Approve Business Combination with Tevogen Bio
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced...
Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced ...
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination
New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Inc (“Tevogen Bio”), an advanced-stage specialty immunotherapy biotech pioneer and Semper Paratus Acquisition Corporation (“Semper Paratus”)...
Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement
New York, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST, the “ Company ”) announced today that it received a letter from the Listing Qualifications Department...
Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the fi...
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
New York, NY, June 29, 2023 (GLOBE NEWSWIRE) -- Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virolo...